News & Updates

Show Multimedia Only

Clustering predicts relapse in eosinophilic fasciitis patients

11 Nov 2022

Patients with eosinophilic fasciitis (EF) can be categorized into homogenous clusters that help predict relapse and sequelae, together with fibrosis and eosinophilia, suggests a study.

Clustering predicts relapse in eosinophilic fasciitis patients

11 Nov 2022

First-line pembrolizumab feasible for BRAF V600–mutant melanoma

10 Nov 2022

A recent study recommends the use of pembrolizumab over BRAF/mitogen-activated protein kinase inhibitors, such as dabrafenib/trametinib, as first-line treatment in patients with advanced BRAF V600‒mutant advanced malignant melanoma.

First-line pembrolizumab feasible for BRAF V600–mutant melanoma

10 Nov 2022

Atezolizumab–bevacizumab combo shows therapeutic potential in advanced mucosal melanoma

04 Nov 2022

The combination of atezolizumab plus bevacizumab demonstrates promising antitumour activity in patients with advanced mucosal melanoma while having a manageable safety profile, according to the results of a phase II study.

Atezolizumab–bevacizumab combo shows therapeutic potential in advanced mucosal melanoma

04 Nov 2022

Phase II data shows treatment potential of litifilimab for CLE

27 Oct 2022 by

In part B* of the two-part 16-week LILAC study, the anti-BDCA2** antibody litifilimab reduced skin disease activity in individuals with cutaneous lupus erythematosus (CLE).

Phase II data shows treatment potential of litifilimab for CLE

27 Oct 2022

Skin biomarkers predict AD risk, severity in newborns

27 Oct 2022 by

Predicting which newborn will go on to develop atopic dermatitis (AD) and how severe it will be is now feasible, according to the BABY* study.

Skin biomarkers predict AD risk, severity in newborns

27 Oct 2022

Long-term tapinarof use proven safe, effective in plaque psoriasis

21 Oct 2022 by

Continuous and intermittent use of tapinarof cream 1% once daily (QD) for up to 1 year is effective in patients with mild-to-severe plaque psoriasis, without serious safety concerns, according to a study. In addition, it has shown durable efficacy and a remittive effect of at least 4 months off therapy.

Long-term tapinarof use proven safe, effective in plaque psoriasis

21 Oct 2022

Ruxolitinib improves repigmentation in vitiligo through 52 weeks

21 Oct 2022 by

Long-term use of ruxolitinib cream continued to improve facial and total body repigmentation in patients with nonsegmental vitiligo from 24 to 52 weeks, according to an updated pooled analysis of the phase III TRuE-V1* and TRuE-V2** studies presented at EADV 2022.

Ruxolitinib improves repigmentation in vitiligo through 52 weeks

21 Oct 2022

Dupilumab reduces itch, improves skin lesions in prurigo nodularis

20 Oct 2022 by

Dupilumab improves itch response and skin lesions in patients with prurigo nodularis (PN) inadequately controlled with prior therapies in the LIBERTY-PN PRIME trial.